Vancomycin for C Difficile NAAT+/EIA- Hematology Oncology Patients
Vancomycin for C Difficile NAAT+/EIA- Hematology Oncology Patients
This study will randomized hematology oncology patients with active diarrhea and a NAAT
 positive/toxin EIA negative to either 14 days of oral vancomycin capsules or placebo. The
 study is designed to include 30 patients (15 per arm).

 Outcomes will include C. difficile load using qPCR, VRE loads, structural and functional
 microbiome changes and frequency of bowel movements. All endpoints will be measured at
 several time points including days 0, 14, 21 and 90.
The adverse health consequences resulting from antibiotic overtreatment of NAAT(+), toxin(-)
 patients may be particularly important in transplant recipients. The usual treatment
 prescribed for CDI at the Froedtert Memorial Lutheran Hospital is oral vancomycin. While this
 drug has excellent activity against C. difficile and commonly suppresses its growth to
 non-detection, it does not eradicate carriage and its use results in marked and prolonged
 disruption of the lower intestinal microbiota. Meanwhile, the degree of lower intestinal
 microbiota disruption at the time of HSCT engraftment has been demonstrated to be an
 independent predictor (controlling for other markers of underlying disease) of overall and
 transplant-related 3-year mortality.14 In addition, recent findings suggest that bone marrow
 suppressive effects of antibiotics, in this case potentially unnecessary oral vancomycin
 (which is not appreciably absorbed), may be solely mediated via microbiota disruption. All
 these data supports the notion that antibiotic treatment of NAAT(+), toxin(-) C. difficile
 patients might have significant negative repercussions without a clear clinical benefit.
Inclusion Criteria:

 -  Patients admitted to the hematology oncology inpatient units at Froedtert Memorial
 Lutheran Hospital

 -  New onset of diarrhea during hospitalization

 -  C. difficile clinical testing showing NAAT positive EIA negative results

 Exclusion Criteria:

 -  Being unable to consent for self

 -  Inability to take enteral medications

 -  Unwillingness to enroll in study

 -  Patient has a documented allergy to vancomycin

 -  Patient has a documented life expectancy shorter than treatment course (14 days)

 -  Patient is unwilling or unable to provide stool samples in the outpatient setting
 after discharge

 -  Diagnosis of C. difficile colitis [NAAT (+) and toxin EIA (+) within 3 months of
 enrollment).

 -  New onset of abdominal distention within 24 hours prior to the onset of diarrhea
 during index admission

 -  Presence of toxic megacolon

 -  Presence of clinical sepsis. Sepsis will be defined as a Sequential [Sepsis-related]
 Organ Failure Assessment (SOFA) score of 2 points or more as per 2016 definitions

 -  Pregnancy or lactating